{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:35Z","timestamp":1791895535222,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.kint.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T20:53:47Z","timestamp":1532379227000},"page":"818-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1016","volume":"94","author":[{"given":"Masafumi","family":"Fukagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.05.013_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.05.013_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","article-title":"Diseases of the parathyroid gland in chronic kidney disease","volume":"15","author":"Komaba","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2018.05.013_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.05.013_bib4","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2215\/CJN.11501210","article-title":"Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns","volume":"6","author":"Akizawa","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.05.013_bib5","first-page":"12","article-title":"Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article","volume":"3","author":"Beladi-Mousavi","year":"2015","journal-title":"J\u00a0Parathyr Dis"},{"key":"10.1016\/j.kint.2018.05.013_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"KRN1493 study group: cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.05.013_bib7","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.05.013_bib8","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1038\/srep19612","article-title":"PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"6","author":"Akizawa","year":"2016","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"10.1016\/j.kint.2018.05.013_bib9","first-page":"S13","article-title":"Clinical study of cinacalcet in Japan","volume":"12","author":"Akizawa","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2018.05.013_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","article-title":"Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"12","author":"Akiba","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2018.05.013_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1016\/j.kint.2018.05.013_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism. A randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2018.05.013_bib13","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A\u00a0novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in\u00a0vivo and in\u00a0vitro","volume":"3;13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2018.05.013_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":"Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in\u00a0vitro and clinical studies","volume":"47","author":"Nakashima","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.kint.2018.05.013_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-006-0129-8","article-title":"Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl","volume":"63","author":"Harris","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.kint.2018.05.013_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","article-title":"Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole","volume":"46","author":"Harris","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.kint.2018.05.013_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy: clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apheresis Dial"},{"key":"10.1016\/j.kint.2018.05.013_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818303879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818303879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:50:12Z","timestamp":1758761412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818303879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0085253818303879"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.05.013","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}